Alzheimer's Biomarkers Gain Prominence In Drug Development Guidance

 
• By Brenda Sandburg

US FDA revises draft guidance issued in 2013 to allow research targeting cognition as single endpoint and studies solely evaluating biomarkers; document offers 'potential for multiple advances,' Alzheimer's Association says.

Memory loss and brain aging due to dementia and alzheimer's disease as a medical icon of a group of color changing autumn fall trees shaped as a human head losing leaves on a white background.

More from Approval Standards

More from Pathways & Standards